Recurrent High-grade Glioma
Conditions
Interventions
Case series:PCV Chemotherapy (Lomustine/vincristine/c kappa hydrazine)
Sponsors
Tiantan Hospital,Capital Medical University; Heibei Yanda Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. A diagnosis of high-grade glioma was established by pathological method,and the recurrency of the disease is ongoing; 2. the report of the pathological diagnosis contained the status of IDH gene, and showed that IDH1/2 mutation existed; 3. the age of the patient is between 18 years old and 70 years old; 4. the condition of the patient permits the procedure of chemotherapy using PCV schema; 5. the patient is informed consent, and willing to join in this research.
Exclusion criteria
Exclusion criteria: 1. The diagnosis is not recurrent high-grade glioma; 2. the diagnosis of high-grade glioma was not established by pathological method; 3. no molecular neuropathological report is available, or the report showed that IDH1/2 mutation did not exist; 4. the age of the patient does not meet the requirement of this research; 5. the condition of the patient does not permit the procedure of chemotherapy using PCV schema; 6. there are other conditions that the clinicans believe that the PCV chemotherapy is not appropriate for the patient; 7. the patient is not willing to join in this research.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| progression free survival;6-month progression-free survival rate;12-month progression-free survival rate;6-month survival rate;12-month survival rate;6-month life quality;12-month life quality; | — |
Countries
China
Contacts
Public ContactJi Nan
Outcome results
None listed